Prophylaxis for hemophilia: state of the art or state of confusion?
Gruppo
R A
RA
D002648:Child; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004334:Drug Administration Schedule; D005164:Factor IX / Q000008:administration & dosage / Q000627:therapeutic use*; D005169:Factor VIII / Q000008:administration & dosage / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000191:economics / Q000517:prevention & control*; D006467:Hemophilia A / Q000150:complications* / Q000191:economics; D002836:Hemophilia B / Q000150:complications* / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male
D005169:Factor VIII; D005164:Factor IX